Show simple item record

dc.contributor.authordos Santos, Jean Leandro [UNESP]
dc.contributor.authorLanaro, Carolina
dc.contributor.authorLima, Lidia Moreira
dc.contributor.authorGambero, Sheley [UNESP]
dc.contributor.authorFranco-Penteado, Carla Fernanda
dc.contributor.authorAexandre-Moreira, Magna Suzana
dc.contributor.authorWade, Marlene
dc.contributor.authorYerigenahally, Shobha
dc.contributor.authorKutlar, Abdullah
dc.contributor.authorMeiler, Steffen E.
dc.contributor.authorCosta, Fernando Ferreira
dc.contributor.authorChung, ManChin [UNESP]
dc.identifier.citationJournal of Medicinal Chemistry. Washington: Amer Chemical Soc, v. 54, n. 16, p. 5811-5819, 2011.
dc.description.abstractA novel series of thalidomide derivatives (4a-f) designed by molecular hybridization were synthesized and evaluated in vitro and in vivo for their potential use in the oral treatment of sickle cell disease symptoms. Compounds 4a-f demonstrated analgesic, anti-inflammatory, and NO-donor properties. Compounds 4c and 4d were considered promising candidate drugs and were further evaluated in transgenic sickle cell mice to determine their capacity to reduce the levels of the proinflammatory cytokine tumor necrosis factor alpha (TNF alpha). Unlike hydroxyurea, the compounds reduced the concentrations of TNF alpha to levels similar to those induced with the control dexamethasone (300 mu mol/kg). These compounds are novel lead drug candidates with multiple beneficial actions in the treatment of sickle cell disease symptoms and offer an alternative to hydroxyurea treatment.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.publisherAmer Chemical Soc
dc.relation.ispartofJournal of Medicinal Chemistry
dc.sourceWeb of Science
dc.titleDesign, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds To Treat Sickle Cell Disease Symptomsen
dcterms.rightsHolderAmer Chemical Soc
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.contributor.institutionUniversidade Federal de Alagoas (UFAL)
dc.contributor.institutionMed Coll Georgia
dc.description.affiliationUniv Estadual Paulista UNESP, Fac Ciencias Farmaceut, Dept Farmacos & Med, Lab Pesquisa & Desenvolvimento Farmacos Lapdesf, BR-14801902 Araraquara, SP, Brazil
dc.description.affiliationUniv Campinas UNICAMP, Haematol & Haemotherapy Ctr, Hemoctr, BR-13083970 Campinas, SP, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Fac Farm, Lab Avaliacao & Sintese Subst Bioat, BR-21944971 Rio de Janeiro, Brazil
dc.description.affiliationUniversidade Federal de Alagoas (UFAL), Inst Ciencias Biol & Saude, Lab Farmacol & Imunidale LaFI, Maceio, AL, Brazil
dc.description.affiliationMed Coll Georgia, Dept Anesthesiol & Perioperat Med, Augusta, GA 30912 USA
dc.description.affiliationMed Coll Georgia, Sickle Cell Ctr, Augusta, GA 30912 USA
dc.description.affiliationUnespUniv Estadual Paulista UNESP, Fac Ciencias Farmaceut, Dept Farmacos & Med, Lab Pesquisa & Desenvolvimento Farmacos Lapdesf, BR-14801902 Araraquara, SP, Brazil
dc.rights.accessRightsAcesso restrito
dc.description.sponsorshipIdFAPESP: 10/12495-6
dc.description.sponsorshipIdFAPESP: 07/56115-0
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt[12][1]
Localize o texto completo

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record